About Us: Clinical Trials 

Retina Group of New England is proud to participate in the most cutting-edge research for vitreo-retinal diseases in Connecticut and Rhode Island. Our extensive work has attributed to some of the latest developments in retinal disease treatment. Based in New London, our research center conducts clinical trials for the treatment of diseases such as Wet Macular Degeneration, Dry Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusions.

 

 

Neovascular (Wet) Macular Degeneration  Treatment Treatment Status Vision Criteria
DAYLIGHT Intravitreal KSI-301 Treatment naive 20/32-20/320
BELVEDRE Susvimo Previously treated with Eylea or Avastin Better than 20/400
ATMOSPHERE Gene Therapy Previously treated 20/20-20-200
SANDOZ Intravitreal Biosimilar Treatment naive 20/40-20/320
VILLA Commercial Susvimo Post SUSVIMO implant observational

 

Dry Macular Degeneration  Treatment Treatment Status Vision Criteria
ALEXION ALXN2040 Oral Treatment naive, no Exud AMD 20/25-20/800

 

Diabetic Retinopathy  Treatment Treatment Status Vision Criteria
GLOW Intravitreal KSI-301 Treatment naive Better than 20/50

 

Retinal Vein Occlusion  Treatment Treatment Status Vision Criteria

 

We are constantly investigating new treatment options. To participate in enrolling clinical trials, or for more information on the newest developments in retinal disease treatment/management, please contact our study coordinator, Emma at (860) 444-1292.

Clinical trials we are currently participating in but that are closed for enrollment: 

DERBY – Intravitreal Pegcetacoplan for Geographic Atrophy

GALE – Intravitreal Pegcetacoplan for Geographic Atrophy – Open Label Extension of Oaks and Derby

RHONE X – Intravitreal Faricimab for Diabetic Macular Edema – Open Label Extension of Rhine

AVONELLE X– Intravitreal Faricimab for Neovascular Macular Degeneration – Open Label Extension of Tenaya

BALATON – Intravitreal Faricimab for Branch Retinal Vein Occlusion

COMINO – Intravitreal Faricimab for Central Retinal Vein Occlusion

PORTAL – Port Delivery System with Lucentis for Neovascular Macular Degeneration – Open Label Extension of Archway

PAGODA – Port Delivery System with Lucentis for Diabetic Macular Edema

GLIMMER – Intravitreal KSI-301 for Diabetic Macular Edema

BEACON – Intravitreal KSI-301 for Retinal Vein Occlusion

PULSAR – Intravitreal high dose Eylea for Neovascular Macular Degeneration

PHOTON – Intravitreal high dose Eylea for Diabetic Macular Edema

NGM – Intravitreal NGM601 for Diabetic Macular Edema

AMGEN – Intravitreal biosimilar for Neovascular Macular Degeneration

 

Clinical trials we previously participated in:

OAKS – Intravitreal Pegcetacoplan for Geographic Atrophy

TENAYA – Intravitreal Faricimab for Neovascular Macular Degeneration

PAVILLION – Ranibizumab for Non Proliferative Diabetic Retinopathy

ARCHER– Intravitreal ANX007 for Geographic Atrophy

CANBERRA – Oral Cannabinoids for Diabetic Retinopathy

CANDELA – High dose Eylea for Neovascular Macular Degeneration

TOPAZ – Suprachoroidal Steroid for Retinal Vein Occlusion

MYLAN– Intravitreal Aflibercept biosimilar for Diabetic Retinopathy

RHINE – Intravitreal Faricimab for Diabetic Retinopathy

ARCHWAY – Port Delivery system Lucentis for Neovascular Macular Degeneration

GRAYBUG – Intravitreal Depot of Sunitinub Malate for Neovascular Macular Degeneration

PANDA 2 – Intravitreal Conversept for Exudative Macular Degeneration

SCORE2 LTE – Standard of care for Retinal Vein Occlusion

PANORAMA – Intravitreal aflibercept vs Sham for Mild-Moderate NPDR

PANDA – Intravitreal Conversept vs. Aflibercept for Neovascular Macular Degeneration

TLC Study – Intravitreal ProDex for Retinal Vein Occlusion with Edema 2017-present (TLC)

Study of  Oral Emixustat Hydrochloride for Proliferative Diabetic Retinopathy 2017 (ACUCELA)

MAKO Study – Topical Squalamine Lactate for Neovascular (wet) Age-Related Macular Degeneration 2016-2017 (OHR)

ONYX Study  Intravitreal REGN910-3 for Neovascular (wet) Age-Related Macular Degeneration 2016-2017 (Regeneron)

RUBY Study – Intravitreal REGN910-3 for Diabetic Macular Edema 2016-2017 (Regeneron)

FILLY Study – Intravitreal APL-2 for Dry Age-Related Macular Degeneration with Geographic Atrophy 2015-2018 (Appelis)

Next study phase starting in summer of 2018

Panorama Study – Intravitreal Eylea to prevent progression of Diabetic Retinopathy 2015-present (Regeneron)

CAPELLA Study – Intravitreal REGN2176-3 for Neovascular (wet) Age-Related Macular Degeneration 2015-2017 (Regeneron)

APEX Study – Oral X82 for Neovascular (wet) Age-Related Macular Degeneration 2015-2018 (Tyrogenex)

Del Mar Study – Intravitreal Luminate for Diabetic Macular Edema 2015-2017 (Allegro)

Phase III study is coming

HAWK study – Intravitreal brolucizumab for Neovascular (wet) Age-Related Macular Degeneration 2015-2018 (Alcon)

Study results went to FDA for approval

DRCR Protocol U – Compared anti-VEGF and intravitreal corticosteroids+anti-VEGF for Diabetic Macular Edema 2015-2016

DRCR Protocol V – Compared treatments for Diabetic Macular Edema with good vision 2014-2017

DRCR Protocol T – Compared effectiveness of Avastin, Lucentis and Eylea for Diabetic Macular Edema 2012-2015

DRCR Protocol S – Compared Panretinal Photocoagulation and Lucentis for PDR 2012-2017

Based on study results Lucentis was FDA approved for Diabetic Retinopathy in 2017

SCORE2 Study and SCORE@ LTE – Compares intravitreal Eylea and Avastin for Central Retinal Vein Occlusion

1 year treatment and 4 years follow up 2014-present (EMMES)

SPECTRI Study – Intravitreal Lampalizumab for Dry Age-Related Macular Degeneration with Geographic Atrophy 2014-2018 (Genentech)

Eclipse and OPH1006 Studies – Intravitreal Fovista for Neovascular (wet) Age-Related Macular Degeneration 2013-2017 (Ophthotech)

Study of oral X82 for Neovascular (wet) Age-Related Macular Degeneration 2012-2015(tyrogenex)

VISTA Study – Intravitreal Eylea for Diabetic Macular Edema 2011-2014 (Regeneron)

Based on study results Eylea was FDA approved for Diabetic Macular Edema in 2014

SHORE Study – Intravitreal Lucentis for Edema secondary to Retinal Vein Occlusion 2011-2012 (Genentech)

COPERNICUS Study – Intravitreal Eylea for Central Retinal Vein Occlusion  2009-2012 (Regeneron)

Based on study results Eylea was FDA approved edema secondary to Central Retinal Vein Occlusion in 2012

RIDE Study – Intravitreal Lucentis for Diabetic Macular Edema 2007-2012 (Genentech)

Based on study results Lucentis was FDA approved for Diabetic Macular Edema in 2012

CRUISE Study – Intravitreal Lucentis for Central Retinal Vein Occlusion 2008-2009 (Genentech)

Based on study results Lucentis was approved by FDA for Retinal Vein Occlusion in 2010

BRAVO Study – Intravitreal Lucentis for Branch Retinal Vein Occlusion 2008-2009 (Genentech)

Based on study results Lucentis was approved by FDA for Retinal Vein Occlusion in 2010

HARBOR Study – Comparing regular and high dose of Intravitreal Lucentis for Neovascular (wet) Age-Related Macular Degeneration 2009-2012 (Genentech)

VIEW 1 Study – Intravitreal Eylea for Neovascular (wet) Age-Related Macular Degeneration 2008-2010 (Regeneron)

Eyelea was approved by FDA for Neovascular (wet) Age-Related Macular Degeneration based on this study results in 2011

FAME Study – Intravitreal insert of Fluocinolone acetonide  2006-2010 (Alimera)

Sustain release insert of FA was approved by FDA in 2014 for Diabetic Macular Edema

SAILOR Study  – Intravitreal Lucentis 2005-2006 (Genentech)

The only research site in South Eastern Connecticut that participated in this final study prior to FDA approval of  Lucentis for Neovascular (wet) Age-Related Macular Degeneration in June of 2006